Regencell Bioscience Holdings Limited (RGC) Financials
RGC Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| Sept. 30, 2023 | 12.6 million | 632320 |
| June 30, 2023 | 12.6 million | 632320 |
| March 31, 2023 | 12621 | 632 |
| Dec. 31, 2022 | 15.5 million | 873789 |
RGC Free Cash Flow and Stock based compensation
No data available :(
RGC Net Income
No data available :(
RGC Cash and Debt
Graph available only for paid members. Upgrade to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| Sept. 30, 2023 | 11.6 million | - | - |
| June 30, 2023 | - | - | 463669 |
| March 31, 2023 | 11564 | - | - |
| Dec. 31, 2022 | - | - | - |
RGC Shares Outstanding
RGC Expenses
Graph available only for paid members. Upgrade to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| Sept. 30, 2023 | - | 231455 | 1041 | 82 |
| June 30, 2023 | - | - | - | - |
| March 31, 2023 | - | 115 | 1041 | 82 |
| Dec. 31, 2022 | - | 1.4 million | 990 | 49 |
RGC Cost of Revenue
Graph available only for paid members. Upgrade to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| Sept. 30, 2023 | - | 769687 |
| June 30, 2023 | - | - |
| March 31, 2023 | - | - |
| Dec. 31, 2022 | - | - |
RGC
Price: $22.16
52 week price:
Earnings Per Share: -0.01 USD
P/E Ratio: -2421
Exchange: NCM
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Country: Hong Kong
Volume: 700
Ebitda: 521.8 millionMarket Capitalization: 11.5 billion